OR WAIT null SECS
© 2022 MJH Life Sciences and BioPharm International. All rights reserved.
© 2022 MJH Life Sciences™ and BioPharm International. All rights reserved.
The need to increase efficiency and productivity is driving adoption.
Effective cleaning and disinfection is imperative when operating and utilizing a cleanroom.
Taking key considerations into account along the cell therapy supply chain can set cell therapy developers up for success.
Growing antibody demand requires long-term scale-up solutions.
mRNA vaccines have led to expanded nucleic acid therapy development.
Implementation of information gathered from novel data analysis techniques has become a priority.
2021 brought innovations in pH sensitive antibody purification, single-use fermentation separators, and more.
May 20, 2022
The agency is asking drug manufacturers to ensure a strong supply chain by developing risk management plans.
Catalent has announced a $175 million project to expand its manufacturing facility for large scale oral dose forms at its Winchester, Ky, site.
FDA has approved Mounjaro (tirzepatide) injections as a treatment to improve blood sugar control in adults with type 2 diabetes.
May 19, 2022
Demand for outsourced services of technical R&D activities is increasing.
May 18, 2022
Pfizer and BioNTech’s COVID-19 vaccine has been granted EUA for booster doses in children five through 11 years of age.
The companies have reached an agreement with the European Commission to update their COVID-19 vaccine supply agreement.
May 16, 2022
Pfizer will acquire Biohaven Pharmaceuticals, a clinical-stage biopharmaceutical company specializing in migraine treatments, for $11.7 billion.
Avacta is relocating its therapeutics headquarters to Scale Space in Imperial College’s White City Campus, London, United Kingdom.
To build trust and ensure a high-quality product, companies must be sure their contracts are firm and their lines of communication even firmer.
May 15, 2022
CDMOs offer expertise and customization options for sponsors of orphan drugs.
CDMOs need to consistently demonstrate agility as demand increases for newly developed therapeutic modalities.
Acquisitions in the CDMO space can give us insight into a company's vision for their future.